BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine.
BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine.
Right before BioNTech was due to announce its 2025 results, the company’s co‑founders, Ugur Sahin and Özlem Türeci, revealed they would leave the company to focus on developing next‑generation mRNA ...
BioNTech's cofounders Ugur Sahin and Oezlem Tuereci will depart the company by 2026 to establish a new venture focusing on next-generation mRNA drugs. Their transition is planned to ensure continuity ...
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA ...
BioNTech SE BNTX shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.
BioNTech's co-founders Ugur Sahin and Oezlem Tuereci plan to leave the company by 2026 to establish a new venture focused on mRNA technology. While ensuring BioNTech's existing operations continue ...
Co-founders, Prof Ugur Sahin and Prof Özlem Türeci, will depart to establish a new, independent biotechnology company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results